Gene Silencing Oligos (GSOs) Third Generation Antisense
|
|
- Clinton Benson
- 8 years ago
- Views:
Transcription
1 Gene Silencing Oligos (GSOs) Third Generation Antisense Walter R. Strapps, Ph.D. Executive Director, RNA Therapeutics Idera Pharmaceuticals Cambridge, MA NASDAQ: IDRA
2 Idera is a leader in developing novel nucleic acid therapeutics to treat patients with orphan diseases NUCLEIC ACID THERAPEUTICS TOLL-LIKE RECEPTOR ANTAGONISM GENE SILENCING TARGETED CANCER THERAPY ORPHAN AUTOIMMUNE DISEASES GENETICALLY DEFINED DISORDERS 2
3 Gene Silencing Oligos: the 3rd generation of antisense OPPORUNITY Oligonucleotides are an important tool in the drug development landscape providing access to previously undruggable targets NEED While RNAi and 2 nd generation chemistries have demonstrated clinical proof of concept, optimal therapeutic index remains an issue for commercial success ADVANTAGE Idera Pharmaceuticals has developed a 3 rd generation technology called gene-silencing oligonucleotide (GSO) in order to mitigate these issues 3
4 Validation of antisense and sirnas as drug discovery platforms Established clinical activity against multiple gene targets Regulatory path of approval established Manufacturing/CMC validated Therapeutic index needs to be improved Dose and delivery Distribution of oligonucleotides Metabolism and excretion Mitigation of off-target and immune-stimulatory effects 4
5 Oligonucleotides: clinical proof of concept for multiple RNA targets Robust pipeline of antisense drug candidates: 1 approved, 10 in phase III, 38 in phase II, 47 in phase I and there is human proof of concept data Target ApoB (antisense and RNAi) PCSK9 (antisense and RNAi) TTR (antisense and RNAi) STAT3 Clinical proof of concept Lipid Lipid Protein Cytokine CRP ApoC - III Protein Triglyceride Second generation antisense is the most successful and widely employed chemistry to date Clinical dosing is high 3-6 mg/kg, biweekly to weekly dosing 5 Idera invention and IP
6 Limitations exist with the current technologies Mipomersen Flu like symptoms Injection site reaction Liver toxicity Santaris PCSK9 Program halted Ph. I Prosensa Dystrophin Ph. III didn t hit endpoints Therapeutic index remains an issue Injection site reactions Immunotoxicity is primarily due to tissue buildup Sequence dependent immune activation 6
7 Idera: Pioneering antisense development Introduced first-generation antisense development ( ) Activation of immune responses observed Created second generation antisense chemistry ( ) Increased stability led to weekly administration, reduced complement activation, and reduced immune activation Issuance of US patent #5,652,355 Licensed to ISIS, being used in all ISIS drug candidates Understanding of immune activation through TLRs (2001-Present) Developed agonists and antagonists of TLRs Introduced third generation antisense chemistry (GSOs) (2011) Incorporates our understanding of antisense mechanisms and TLRs Issuance of US patent #8,431,544 7
8 The solution: Gene Silencing Oligonucleotides Our GSO has a novel structure Novel single-stranded structure designed to result in greater potency: 19-mer to 23-mer length is tolerated Mitigation of immune activation: GSOs lack 5 -end, thereby avoiding immune activation through TLRs Systemic Delivery of GSOs: No vehicle is required US Patent # 8,431,544 Issued 2013; Published in J. Med. Chem. 2011, 54,
9 Insights into the features of GSOs Mitigation of immune activation Two Free 3 -ends are required for GSO activity Effect of length of GSO Effect of linker on the activity of GSO Improved Activity, Potency and Duration of GSO versus ASO Rapid, efficient path to in vivo proof of concept: proprietary design algorithm removes problematic sequences (GSOs for >15 targets ID d) Issued US Patent on GSO structure 9
10 GSO technology validated in preclinical models Mitigation of immune activation Improved therapeutic index Efficient path to in vivo proof of concept Attaching two antisense molecules at the 5 ends avoids TLR engagement Examples: PKCα, Bcl2, H-ras, C-raf Novel GSO structure results in increased potency with less tissue accumulation Examples: ApoB, mir-21, MyD88, TLR9, PCSK9 Creation of GSO drug candidates in under six months for a gene target Examples: ApoB, PCSK9, MyD88, TLR9, mir-21, and other mirnas 10
11 Unique design of GSOs avoids TLR engagement and decreases immune activation Same Bcl2 sequence comparing GSO vs. antisense dose response pg/ml KC MCP-1 IL-12 IP-10 TNF- IL-1 MIP-1 IL-6 IL-1 IL-2 IL-17 MIG 0 PBS 10 mg/kg 50 mg/kg 100 mg/kg 10 mg/kg 50 mg/kg 100 mg/kg PS Antisense GSO Experimental design: 2 hr 10, 50, 100 mg/kg BCL2 GSO or 11 Antisense, s.c. Serum Cytokine Analysis Sequences: Bcl2 antisense 5 -TCTCCCAGCGTGCGCCAT-3 Bcl2 GSO 3 -TACCGCGTGCGACCCTCT-X-TCTCCCAGCGTGCGCCAT-3 11
12 Turning an existing ASO into a GSO results in a more active and potent gene silencer A lead ASO sequence from the literature was made as a GSO and tested side by side. The GSO is ~3 times as active and ~5 times as potent as the ASO. 12
13 GSO is more potent than antisense in vivo Study design 24 hr 2 hr Serum Cytokine Analysis 0.5, 2 or 5 mg/kg GSO or 0.5, 2, 5, 15 or 30 mg/kg Antisense PS-oligo, s.c mg/kg TLR9 Agonist, s.c. Female C57Bl/6 mice 6-8 weeks old; N = 3/group. 13
14 Two free 3 -ends are required for GSO activity Study design 5 mg/kg compounds 1-4 or PBS, s.c hr 2 hr 10 mg/kg TLR7 Agonist, s.c. 5 5 Serum Cytokine Analysis IL-12 X X X % Inhibition of TLR7 agonist mediated IL 12 induction Female C57Bl/6 mice 6-8 weeks old; N = 3/group.
15 GSO has longer duration of action than ASO in vivo 24 hr 2 hr Serum Cytokine Analysis 5 mg/kg GSO or Antisense PS-oligo, s.c mg/kg TLR9 Agonist, s.c. 15
16 Creation of GSO drug candidates in under six months for a gene target GSOs for Target Gene Validation of Activity in Cell Culture In vivo Studies in Disease Models Lead Candidate 4-8 weeks 8-16 weeks 16
17 Example: Identification and validation of ApoB GSOs Screened 4 candidates GSOs in order to select a lead candidate Selection of lead by reduction of ApoB liver mrna and serum total cholesterol % inhibition of ApoB mrna Liver ApoB mrna Levels GSO-1GSO-2GSO-3GSO-4 PBS GSO4 ApoB100 tubulin % inhibition of serum cholesterol Serum Total Cholesterol 0 Levels GSO-1GSO-2GSO-3GSO-4 15 mg/kg, s.c., six doses, every other day in mice, liver and serum analysis 17
18 Evaluation of ApoB GSO dose response Study design ApoB GSO 7.5 and 15 mg/kg, or PBS, s.c. Day Collect blood for serum cholesterol assessment Dosing Period Collect liver for mrna and protein analysis and blood for serum cholesterol Collect blood for serum cholesterol recovery assessment Recovery Period Total Dose: 45 mpk or 90 mpk N = 6, C57BL/6 male mice, 6 weeks old, Animals were on high fat diet two weeks prior to treatment and until termination of the study. 18
19 ApoB GSO treatment reduces cholesterol in mouse model of elevated cholesterol 160 Total Cholesterol Serum Total Cholesterol, mg/dl Dosing period Post-dosing recovery period Day PBS 7.5 mg/kg 15 mg/kg P < 0.05 vs PBS ApoB protein GSO mg/kg ApoB mrna GSO mg/kg Specificity of ApoB GSO (15 mg/kg) and15 mg/kg, s.c., six doses, twice a week in high fat diet mice, liver and serum analysis
20 Targeting mir-21 with a GSO mir-21 Sequence 5 -UAGCUUAUCAGACUGAUGUUGA-3 Underlined segment is GSO target; nucleotides shown in orange represent seed region. mir-21 GSO 3 -CGAATAGTCTGACTACAAC-X-CAACATCAGTCTGATAAGC-3 DNA phosphorothioate; X represents glycerol linker. HeLa Cells HCT-116 Cell Line % change in mir-21 levels mir-21 GSO Control GSO 10 g/ml mir-21 GSO Control GSO g/ml -100
21 mir-21 GSO Exerts Antitumor Effect in Murine Colon Carcinoma Model CT26 3x10 5, i.p. mir-21 GSO or Control GSO, 5 mg/kg, or PBS, i.p. BALB/c N = 10 Day Monitor survival 100 Percent survival Treatment 44 days 22 days > 76 days p = Days post tumor implantation p = PBS mir-21 GSO Control GSO Median survival days Log-rank test mir-21 GSO shows antitumor activity in murine colon cancer model
22 Gene Silencing Oligonucleotides design decreases tissue accumulation without affecting potency Relative PCSK9 mrna Quantity PCSK9 mrna PBS GSO mg/kg Antisense, mg/kg GSO 15 mg/kg AS 50 mg/kg AS 100 mg/kg % inhibition of LDL-c compared to PBS LDL-cholesterol Day Day Dosing period Post-dosing recovery period Dose GSO or 1 st Gen ASO, s.c. Collect serum for analysis Harvest liver for mrna knockdown C57BL/6, female, normal Day Study design: diet, N=6 22
23 Unique GSO design decreases tissue accumulation without affecting potency Study design: PCSK9 GSO (15 mg/kg, s.c.) or PCSK9 antisense (15 mg/kg, s.c.) C57BL/6 mice (2 per collection group) Initial dose Collection of liver and kidney, extraction of oligo from tissues, Analysis of oligo by anion-exchange HPLC Hour % Full-length GSO Remaining in Kidney Kidney Time (hrs) % Full-length GSO Remaining in Liver Liver PCSK9 Antisense PCSK9 GSO Time (hrs) PCSK9 GSO: 3 -CCACGACTACCTCCTCTGG-X-GGTCTCCTCCATCAGCACC-3 PCSK9 2 ND Gen Antisense: 3 -CCACGACTACCTCCTCTGG-5 X = Glycerol Linker; Orange font nucleotides indicate 2 -O-Me-nucleotides; gray font indicates DNA; phosphorothioate backbone 23
24 GSO shows no immunotoxicity in organs GSO, 15 mg/kg, s.c. Week Measurements at week 14 C57BL/6 mice, 4/group Organ weight, Serum IL-12 Skin Spleen Liver Kidney Saline GSO 15 mg/kg Per dose (total dose = 195 mpk) 24 human VEGF GSO 3 -GAAAGACGACAGAACCCAC-X-CACCCAAGACAGCAGAAAG-3
25 GSOs provide a new platform for gene silencing therapeutics GSOs show greater activity, potency and duration than ASOs GSOs mitigate immune responses seen with ASOs GSOs show no obvious signs of organ toxicity after repeat dosing GSOs offer potential for both hepatic and extra-hepatic targets Next Steps: Prioritization of disease targets for human proof-of-concept studies SAR to further optimize drug-like properties of GSOs and potency 25
26 Prioritization of disease indications for treatment with GSOs Key Considerations: Strong evidence that the disease is caused by a specific protein Unmet medical need Clear criteria to identify a target patient population Biomarker for early assessment of clinical proof of concept Targeted therapeutic mechanism of action plus medical need allow for a rapid development path to approval 26
27 Idera is a leader in developing novel nucleic acid therapeutics to treat patients with orphan diseases NUCLEIC ACID THERAPEUTICS TOLL-LIKE RECEPTOR ANTAGONISM GENE SILENCING TARGETED CANCER THERAPY ORPHAN AUTOIMMUNE DISEASES GENETICALLY DEFINED DISORDERS 27
岑 祥 股 份 有 限 公 司 技 術 專 員 費 軫 尹 20100803
技 術 專 員 費 軫 尹 20100803 Overview of presentation Basic Biology of RNA interference Application of sirna for gene function? How to study mirna? How to deliver sirna and mirna? New prospects on RNAi research
More informationFACT SHEET TESTETROL, A NOVEL ORALLY BIOACTIVE ANDROGEN
FACT SHEET TESTETROL, A NOVEL ORALLY BIOACTIVE ANDROGEN General Pantarhei Bioscience B.V. is an emerging specialty pharmaceutical company with a creative approach towards drug development. The Company
More informationTOOLS sirna and mirna. User guide
TOOLS sirna and mirna User guide Introduction RNA interference (RNAi) is a powerful tool for suppression gene expression by causing the destruction of specific mrna molecules. Small Interfering RNAs (sirnas)
More informationRNA-based therapeutics hold significant potential as promising
Supplement to the May 2011 Issue of pharmtech.com 2011 The Industry s Authoritative Source MicroRNA Therapeutics Perspectives in MicroRNA Therapeutics Kevin Steffy, Charles Allerson, and Balkrishen Bhat
More informationMicroRNA formation. 4th International Symposium on Non-Surgical Contraceptive Methods of Pet Population Control
MicroRNA formation mirna s are processed from several precursor stages Mammalian genomes seem to have 100 s of mirna s Nucleotides in positions 2-8 of an mirna are considered the mirna seed 5 Methyl-G
More informationWhy is HDL Cholesterol Low in People with Insulin Resistance and Type 2 Diabetes Mellitus?
Why is HDL Cholesterol Low in People with Insulin Resistance and Type 2 Diabetes Mellitus? Henry Ginsberg, MD Columbia University College of Physicians and Surgeons Henry Ginsberg: Disclosures Research
More informationPharmacology skills for drug discovery. Why is pharmacology important?
skills for drug discovery Why is pharmacology important?, the science underlying the interaction between chemicals and living systems, emerged as a distinct discipline allied to medicine in the mid-19th
More informationThomson Reuters Biomarker Solutions: Hepatitis C Treatment Biomarkers and special considerations in patients with Asthma
: Hepatitis C Treatment Biomarkers and special considerations in patients with Asthma Abstract This case study aims to demonstrate the process of biomarker identification and validation utilizing Thomson
More informationNon-clinical development of biologics
Aurigon Life Science GmbH Non-clinical development of biologics Requirements, challenges and case studies Committed to Life. Sigrid Messemer vet. med. M4 Seminar March 10 th 2014 Aurigon - your full service
More informationDiabetes and Drug Development
Diabetes and Drug Development Metabolic Disfunction Leads to Multiple Diseases Hypertension ( blood pressure) Metabolic Syndrome (Syndrome X) LDL HDL Lipoproteins Triglycerides FFA Hyperinsulinemia Insulin
More informationMedical Therapies Limited EGM Presentation
Medical Therapies Limited EGM Presentation Maria Halasz Chief Executive Officer 5 May 2009 1 Agenda 1. Company information 2. Recent developments 3. Business strategy 4. Key value inflection points for
More informationMOLOGEN AG. Q1 Results 2015 Conference Call Dr. Matthias Schroff Chief Executive Officer. Berlin, 12 May 2015
Q1 Results 2015 Conference Call Dr. Matthias Schroff Chief Executive Officer Berlin, 12 May 2015 V1-6 Disclaimer Certain statements in this presentation contain formulations or terms referring to the future
More informationSDS gel electrophoresis was performed using a 4% by 20% gradient gel 8. Quantification of Western blots was performed using Image J Processing and
Supplemental Material: Western blot: SDS gel electrophoresis was performed using a 4% by 20% gradient gel 8. Quantification of Western blots was performed using Image J Processing and Analysis (NIH). Quantitative
More informationGT-020 Phase 1 Clinical Trial: Results of Second Cohort
GT-020 Phase 1 Clinical Trial: Results of Second Cohort July 29, 2014 NASDAQ: GALT www.galectintherapeutics.com 2014 Galectin Therapeutics inc. Forward-Looking Statement This presentation contains, in
More informationA Genetic Analysis of Rheumatoid Arthritis
A Genetic Analysis of Rheumatoid Arthritis Introduction to Rheumatoid Arthritis: Classification and Diagnosis Rheumatoid arthritis is a chronic inflammatory disorder that affects mainly synovial joints.
More informationHUNTINGTON S DISEASE THERAPIES RESEARCH UPDATE
HUNTINGTON S DISEASE MULTIDISCIPLINARY CLINIC HUNTINGTON S DISEASE THERAPIES RESEARCH UPDATE From gene to treatments The gene that causes Huntington s disease (HD) was discovered in 1993. Since then, enormous
More informationRNAi Shooting the Messenger!
RNAi Shooting the Messenger! Bronya Keats, Ph.D. Department of Genetics Louisiana State University Health Sciences Center New Orleans Email: bkeats@lsuhsc.edu RNA interference (RNAi) A mechanism by which
More informationNONCLINICAL EVALUATION FOR ANTICANCER PHARMACEUTICALS
INTERNATIONAL CONFERENCE ON HARMONISATION OF TECHNICAL REQUIREMENTS FOR REGISTRATION OF PHARMACEUTICALS FOR HUMAN USE ICH HARMONISED TRIPARTITE GUIDELINE NONCLINICAL EVALUATION FOR ANTICANCER PHARMACEUTICALS
More informationSummary of Discussion on Non-clinical Pharmacology Studies on Anticancer Drugs
Provisional Translation (as of January 27, 2014)* November 15, 2013 Pharmaceuticals and Bio-products Subcommittees, Science Board Summary of Discussion on Non-clinical Pharmacology Studies on Anticancer
More informationTHE CANCER STEM CELL INHIBITORS VS-6063 AND VS-5584 EXHIBIT SYNERGISTIC ANTICANCER ACTIVITY IN PRECLINICAL MODELS OF MESOTHELIOMA
THE CANCER STEM CELL INHIBITORS VS-6063 AND VS-5584 EXHIBIT SYNERGISTIC ANTICANCER ACTIVITY IN PRECLINICAL MODELS OF MESOTHELIOMA Mitchell Keegan, Ph.D. Vice President of Development, Verastem, Inc. 1
More informationALLIANCE FOR LUPUS RESEARCH AND PFIZER S CENTERS FOR THERAPEUTIC INNOVATION CHALLENGE GRANT PROGRAM PROGRAM GUIDELINES
ALLIANCE FOR LUPUS RESEARCH AND PFIZER S CENTERS FOR THERAPEUTIC INNOVATION CHALLENGE GRANT PROGRAM PROGRAM GUIDELINES DESCRIPTION OF GRANT MECHANISM The Alliance for Lupus Research (ALR) is an independent,
More informationNuevas tecnologías basadas en biomarcadores para oncología
Nuevas tecnologías basadas en biomarcadores para oncología Simposio ASEBIO 14 de marzo 2013, PCB Jose Jimeno, MD, PhD Co-Founder / Vice Chairman Pangaea Biotech SL Barcelona, Spain PANGAEA BIOTECH BUSINESS
More informationAutoimmunity and immunemediated. FOCiS. Lecture outline
1 Autoimmunity and immunemediated inflammatory diseases Abul K. Abbas, MD UCSF FOCiS 2 Lecture outline Pathogenesis of autoimmunity: why selftolerance fails Genetics of autoimmune diseases Therapeutic
More informationOncos Therapeutics: ONCOS THERAPEUTICS Personalized Cancer Immunotherapy. March 2015. Antti Vuolanto, COO and co-founder
Oncos Therapeutics: Personalized Cancer Immunotherapy ONCOS THERAPEUTICS Personalized Cancer Immunotherapy March 2015 Antti Vuolanto, COO and co-founder 1 History of Oncos Therapeutics 2002 2007 2009 Research
More informationGuidance for Industry
Guidance for Industry S9 Nonclinical Evaluation for Anticancer Pharmaceuticals U.S. Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation and Research (CDER) Center
More informationAchieving Regulatory Success: Areas of focus for biotechnology companies. Michael J. Schlosser, PhD, DABT April 21, 2013
Achieving Regulatory Success: Areas of focus for biotechnology companies Michael J. Schlosser, PhD, DABT April 21, 2013 Regulatory Success Outline Regulatory Initiatives Regulatory Science Pre-Regulatory
More informationAnti-CD38 anti-cd3 bispecific antibody in multiple myeloma
Anti-CD38 anti-cd3 bispecific antibody in multiple myeloma David E. Szymkowski Senior Director, Biotherapeutics Proteins by Design 1960s...1980s...2000s... Where are the bispecific antibody drugs? J Exp.
More informationA Letter from MabVax Therapeutics President and Chief Executive Officer
A Letter from MabVax Therapeutics President and Chief Executive Officer Dear Fellow Stockholder: You have invested in MabVax Therapeutics because you share our passion for finding new therapies for the
More informationBasic Overview of Preclinical Toxicology Animal Models
Basic Overview of Preclinical Toxicology Animal Models Charles D. Hebert, Ph.D., D.A.B.T. December 5, 2013 Outline Background In Vitro Toxicology In Vivo Toxicology Animal Models What is Toxicology? Background
More informationMuscular dystrophy clinical manifestations: progressive proximal extremity weakness respiratory muscle weakness cardiomyopathy
Muscular dystrophy clinical manifestations: progressive proximal extremity weakness respiratory muscle weakness cardiomyopathy Muscular dystrophy pathology: muscle fiber degeneration and regeneration Muscular
More informationBiologic Treatments for Rheumatoid Arthritis
Biologic Treatments Rheumatoid Arthritis (also known as cytokine inhibitors, TNF inhibitors, IL 1 inhibitor, or Biologic Response Modifiers) Description Biologics are new class of drugs that have been
More informationUnderstanding the immune response to bacterial infections
Understanding the immune response to bacterial infections A Ph.D. (SCIENCE) DISSERTATION SUBMITTED TO JADAVPUR UNIVERSITY SUSHIL KUMAR PATHAK DEPARTMENT OF CHEMISTRY BOSE INSTITUTE 2008 CONTENTS Page SUMMARY
More informationTargeting Specific Cell Signaling Pathways for the Treatment of Malignant Peritoneal Mesothelioma
The Use of Kinase Inhibitors: Translational Lab Results Targeting Specific Cell Signaling Pathways for the Treatment of Malignant Peritoneal Mesothelioma Sheelu Varghese, Ph.D. H. Richard Alexander, M.D.
More informationOverview of Phase 1 Oncology Trials of Biologic Therapeutics
Overview of Phase 1 Oncology Trials of Biologic Therapeutics Susan Jerian, MD ONCORD, Inc. February 28, 2008 February 28, 2008 Phase 1 1 Assumptions and Ground Rules The goal is regulatory approval of
More informationTransgenic technology in the production of therapeutic proteins
Transgenic technology in the production of therapeutic proteins Transgenic technology represents a new generation of biopharmaceutical production system to meet the medical needs of the new millennium.
More informationNEW CLINICAL RESEARCH OPTIONS IN PANCREATIC CANCER IMMUNOTHERAPY. Alan Melcher Professor of Clinical Oncology and Biotherapy Leeds
NEW CLINICAL RESEARCH OPTIONS IN PANCREATIC CANCER IMMUNOTHERAPY Alan Melcher Professor of Clinical Oncology and Biotherapy Leeds CANCER IMMUNOTHERAPY - Breakthrough of the Year in Science magazine 2013.
More informationNursing 113. Pharmacology Principles
Nursing 113 Pharmacology Principles 1. The study of how drugs enter the body, reach the site of action, and are removed from the body is called a. pharmacotherapeutics b. pharmacology c. pharmacodynamics
More informationThe Clinical Trials Process an educated patient s guide
The Clinical Trials Process an educated patient s guide Gwen L. Nichols, MD Site Head, Oncology Roche TCRC, Translational and Clinical Research Center New York DISCLAIMER I am an employee of Hoffmann-
More informationThe RNA strategy. RNA as a tool and target in human disease diagnosis and therapy.
The RNA strategy RNA as a tool and target in human disease diagnosis and therapy. The Laboratory of RNA Biology and Biotechnology at the Centre for Integrative Biology (CIBIO) of the University of Trento,
More informationGenScript Antibody Services
GenScript Antibody Services Scientific experts, innovative technologies, proven performance We specialize in custom antibody production to empower your research Custom Polyclonal Antibody Production Custom
More informationMaking the most of academic drug target discoveries
Making the most of academic drug target discoveries Richard Reschen, Isis Innovation, University of Oxford The explosion of new technologies and research techniques, and encouragement from funding agencies
More informationHow To Understand The Chemistry Of Organic Molecules
CHAPTER 3 THE CHEMISTRY OF ORGANIC MOLECULES 3.1 Organic Molecules The chemistry of carbon accounts for the diversity of organic molecules found in living things. Carbon has six electrons, four of which
More informationRNAi: principle DNA RNA PROTEIN
RNAi: principle RNAi DNA RNA PROTEIN Transcription (nucleus) Translation (cytoplasm) Many diseases develop from the undesirable production of specific proteins (oncogene products, mutant proteins, toxins,
More informationAAGPs TM Anti-Aging Glyco Peptides. Enhancing Cell, Tissue and Organ Integrity Molecular and biological attributes of lead AAGP molecule
AAGPs TM Anti-Aging Glyco Peptides Enhancing Cell, Tissue and Organ Integrity Molecular and biological attributes of lead AAGP molecule 1 Acknowledgements This presentation was prepared by Dr. Samer Hussein
More information4.1 Objectives of Clinical Trial Assessment
L1 4.1 Objectives of Clinical Trial Assessment Presentation to APEC Preliminary Workshop on Review of Drug Development in Clinical Trials Celia Lourenco, PhD, Manager, Clinical Group I Office of Clinical
More informationGene Therapy- Past, Present and Future. Mark A. Kay MD, PhD Dennis Farrey Family Professor Departments of Pediatrics and Genetics Stanford University
Gene Therapy- Past, Present and Future Mark A. Kay MD, PhD Dennis Farrey Family Professor Departments of Pediatrics and Genetics Stanford University Definition of gene therapy Gene therapy is the introduction
More information6,875,000 Shares Common Stock $8.00 per share
Prospectus 6,875,000 Shares Common Stock $8.00 per share 8SEP201418231325 This is the initial public offering of Vitae Pharmaceuticals, Inc. We are offering 6,875,000 shares of common stock. Prior to this
More informationGenomic Medicine The Future of Cancer Care. Shayma Master Kazmi, M.D. Medical Oncology/Hematology Cancer Treatment Centers of America
Genomic Medicine The Future of Cancer Care Shayma Master Kazmi, M.D. Medical Oncology/Hematology Cancer Treatment Centers of America Personalized Medicine Personalized health care is a broad term for interventions
More information2.1.2 Characterization of antiviral effect of cytokine expression on HBV replication in transduced mouse hepatocytes line
i 1 INTRODUCTION 1.1 Human Hepatitis B virus (HBV) 1 1.1.1 Pathogenesis of Hepatitis B 1 1.1.2 Genome organization of HBV 3 1.1.3 Structure of HBV virion 5 1.1.4 HBV life cycle 5 1.1.5 Experimental models
More informationFORM 6-K. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549. Report of Foreign Private Issuer
FORM 6-K SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the month of September
More informationIs Insulin Effecting Your Weight Loss and Your Health?
Is Insulin Effecting Your Weight Loss and Your Health? Teressa Alexander, M.D., FACOG Women s Healthcare Associates www.rushcopley.com/whca 630-978-6886 Obesity is Epidemic in the US 2/3rds of U.S. adults
More informationNewsletter. WntResearch AB, Medeon Science Park, Per Albin Hanssons väg 41, 205 12 Malmö, Sweden. Primary Objective:
Newsletter This resume of the results from the phase 1 study with Foxy-5 is based on clinical and laboratory data from the study, and these data have now been locked into the database. The full report
More informationCONTRACTING ORGANIZATION: University of Alabama at Birmingham Birmingham, AL 35294
AD Award Number: W81XWH-08-1-0030 TITLE: Regulation of Prostate Cancer Bone Metastasis by DKK1 PRINCIPAL INVESTIGATOR: Gregory A. Clines, M.D., Ph.D. CONTRACTING ORGANIZATION: University of Alabama at
More informationThe Molecules of Cells
The Molecules of Cells I. Introduction A. Most of the world s population cannot digest milk-based foods. 1. These people are lactose intolerant because they lack the enzyme lactase. 2. This illustrates
More informationQ4 2015 PRESENTATION February 9, 2016 Per Walday, CEO Ronny Skuggedal, CFO
Q4 2015 PRESENTATION February 9, 2016 Per Walday, CEO Ronny Skuggedal, CFO 1 PCI BIOTECH Important notice and disclaimer This presentation may contain certain forward-looking statements and forecasts based
More informationIntroduction to Enteris BioPharma
Introduction to Enteris BioPharma Enteris BioPharma Intelligent Solutions for Oral Drug Delivery Privately held, New Jersey based biotech company Owned solely by Victory Park Capital, a large Chicago based
More informationExelixis Showcases R&D Pipeline at JPMorgan Healthcare Conference
Exelixis Showcases R&D Pipeline at JPMorgan Healthcare Conference Two New Clinical Programs and Significant Expansion of Cancer Pipeline Planned for 2004 SOUTH SAN FRANCISCO, Calif., Jan. 13 /PRNewswire-FirstCall/
More informationYour Life Your Health Cariodmetabolic Risk Syndrome Part VII Inflammation chronic, low-grade By James L. Holly, MD The Examiner January 25, 2007
Your Life Your Health Cariodmetabolic Risk Syndrome Part VII Inflammation chronic, low-grade By James L. Holly, MD The Examiner January 25, 2007 The cardiometabolic risk syndrome is increasingly recognized
More informationInterim Statement 29 th September 2015
Interim Statement 29 th September 2015 Silence Therapeutics plc Interim results for the six months ended 30 June 2015 Significant fundraising, encouraging clinical data and R&D progress London, 29 September
More informationBiotherapeutics Drug Development
Biotherapeutics Drug Development Susan Hurst, Ph.D. University of Connecticut Bioanalytical Chemistry Spring 2011 April 19, 2011 Outline Background Therapeutic Modalities Examples of Challenges for Biotherapeutics
More informationWe use Reaxys intensively for hit identification, hit-to-lead and lead optimization.
CASE STUDY Dr. Fabio C. Tucci, COO of Epigen Biosciences We use Reaxys intensively for hit identification, hit-to-lead and lead optimization. CREATING NEW ASSETS Epigen Biosciences is a start-up pharmaceutical
More informationa Phase 2 prostate cancer clinical trial is ongoing. Table 2: Squalamine vs Standard-of-care literature
PRODUCT FACT SHEET Spring 2007 MISSION STATEMENT Genaera Corporation is a biopharmaceutical company with a focus on metabolic and respiratory diseases. The compounds in the Genaera pipeline address signal
More informationPrior Authorization Guideline
Prior Authorization Guideline Guideline: PS Inj - Alimta Therapeutic Class: Antineoplastic Agents Therapeutic Sub-Class: Antifolates Client: PS Inj Approval Date: 8/2/2004 Revision Date: 12/5/2006 I. BENEFIT
More informationIdentification of CD4+ T cell epitopes specific for the breast cancer associated antigen NY-BR-1
9/8/2015 Identification of CD4+ T cell epitopes specific for the breast cancer associated antigen NY-BR-1 Stefan Eichmüller, PhD GMP & T Cell Therapy Unit, German Cancer Research Center, Heidelberg, Germany
More informationBNC105 PHASE II RENAL CANCER TRIAL RESULTS
ABN 53 075 582 740 ASX ANNOUNCEMENT 19 March 2014 BNC105 PHASE II RENAL CANCER TRIAL RESULTS Results show BNC105 utility in patients with advanced disease Identified biomarkers which correlate with patient
More informationDrug Development Services
Drug Development Services USING BLOOD AND BONE MARROW PRIMARY CELL SYSTEMS Clinically Relevant In Vitro Assays Broad Spectrum of Drug Classes Multi-Species Platforms Enhancing Drug Development through
More informationGuidance for Industry Safety Testing of Drug Metabolites
Guidance for Industry Safety Testing of Drug Metabolites U.S. Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation and Research (CDER) February 2008 Pharmacology
More informationWntResearch. Foxy-5 A unique Phase 1 opportunity to combat the spreading of cancer
WntResearch Foxy-5 A unique Phase 1 opportunity to combat the spreading of cancer Why WntResearch is developing novel anti-cancer drugs Approximately 55 000 Swedish citizens are diagnosed with cancer every
More informationwww.iproteos.com Corporate Presentation November, 2013
www.iproteos.com Corporate Presentation November, 2013 The company Iproteos is an early-stage drug development company founded in 2011: Spin-Out from Institute for Research in Biomedicine (IRB Barcelona)
More informationClinically Actionable Biomarkers in Rheumatoid Arthritis
Clinically Actionable Biomarkers in Rheumatoid Arthritis PepTalk January 6, 2009 William Robinson, MD, PhD Stanford University School of Medicine VA Palo Alto Health Care System T cell mediated Autoimmune
More informationTowards Well-Defined ADCs (Antibody Drug Conjugates)
Towards Well-Defined ADCs (Antibody Drug Conjugates) Next generation approach June 10, 2015 Dr. Yong Zu Kim, CEO and President LegoChem Biosciences, Inc. Antibody Drug Conjugates ADC binds to Antigen Endocytosis
More informationProgramming effects of endocrine disrupting compounds in mice
Programming effects of endocrine disrupting compounds in mice Joantine van Esterik 19 June 2014 1 Perinatal bisphenol A in mice 18 January 2011 Developmental Origins of Health and Disease (DOHaD) Adverse
More informationCTC Technology Readiness Levels
CTC Technology Readiness Levels Readiness: Software Development (Adapted from CECOM s Software Technology Readiness Levels) Level 1: Basic principles observed and reported. Lowest level of software readiness.
More informationPredictive Biomarkers for Tumor Immunotherapy: Are we ready for clinical implementation? Howard L. Kaufman Rush University
Predictive Biomarkers for Tumor Immunotherapy: Are we ready for clinical implementation? Howard L. Kaufman Rush University Changing Paradigms in Cancer Treatment Potential Uses of Biomarkers Adverse event
More informationCover Page. The handle http://hdl.handle.net/1887/20863 holds various files of this Leiden University dissertation.
Cover Page The handle http://hdl.handle.net/1887/20863 holds various files of this Leiden University dissertation. Author: Maczuga, Piotr Title: Towards RNAi based therapy of liver diseases : diversity
More informationHuman Genome Organization: An Update. Genome Organization: An Update
Human Genome Organization: An Update Genome Organization: An Update Highlights of Human Genome Project Timetable Proposed in 1990 as 3 billion dollar joint venture between DOE and NIH with 15 year completion
More informationGene Therapy. The use of DNA as a drug. Edited by Gavin Brooks. BPharm, PhD, MRPharmS (PP) Pharmaceutical Press
Gene Therapy The use of DNA as a drug Edited by Gavin Brooks BPharm, PhD, MRPharmS (PP) Pharmaceutical Press Contents Preface xiii Acknowledgements xv About the editor xvi Contributors xvii An introduction
More informationPeptide and Sustained Release Technology to Treat Ocular Diseases and Cancer
Peptide and Sustained Release Technology to Treat Ocular Diseases and Cancer Jordan Green, PhD, Co-Founder and CEO Wendy Perrow, MBA, Senior Business Advisor February 11, 2015 www.asclepix.com Advantages
More informationDr Alexander Henzing
Horizon 2020 Health, Demographic Change & Wellbeing EU funding, research and collaboration opportunities for 2016/17 Innovate UK funding opportunities in omics, bridging health and life sciences Dr Alexander
More informationMicro RNAs: potentielle Biomarker für das. Blutspenderscreening
Micro RNAs: potentielle Biomarker für das Blutspenderscreening micrornas - Background Types of RNA -Coding: messenger RNA (mrna) -Non-coding (examples): Ribosomal RNA (rrna) Transfer RNA (trna) Small nuclear
More informationTHE ENDOCANNABINOID SYSTEM AS A THERAPEUTIC TARGET FOR LIVER DISEASES. Key Points
December 2008 (Vol. 1, Issue 3, pages 36-40) THE ENDOCANNABINOID SYSTEM AS A THERAPEUTIC TARGET FOR LIVER DISEASES By Sophie Lotersztajn, PhD, Ariane Mallat, MD, PhD Inserm U841, Hôpital Henri Mondor,
More informationA leader in the development and application of information technology to prevent and treat disease.
A leader in the development and application of information technology to prevent and treat disease. About MOLECULAR HEALTH Molecular Health was founded in 2004 with the vision of changing healthcare. Today
More informationH. Richard Alexander, Jr., M.D. Department of Surgery and The Greenebaum Cancer Center University of Maryland School of Medicine Baltimore, Md
Major Advances in Cancer Prevention, Diagnosis and Treatment~ Why Mesothelioma Leads the Way H. Richard Alexander, Jr., M.D. Department of Surgery and The Greenebaum Cancer Center University of Maryland
More informationCAN-FITE BIOPHARMA LTD.
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 Under the Securities Exchange Act of 1934 For the Month
More informationSuperior TrueMAB TM monoclonal antibodies for the recognition of proteins native epitopes
Superior TrueMAB TM monoclonal antibodies for the recognition of proteins native epitopes Outlines Brief introduction of OriGene s mission on gene-centric product solution. TrueMAB monoclonal antibody
More informationWelchol (colesevelam HCl) Receives FDA Approval to Reduce Blood Glucose in Adults with Type 2 Diabetes
For Immediate Release Company name: DAIICHI SANKYO COMPANY, LIMITED Representative: Takashi Shoda, President and Representative Director (Code no.: 4568, First Section, Tokyo, Osaka and Nagoya Stock Exchanges)
More information1) Aug 2005 In Vitro Chromosomal Aberration Study Cytotoxicity (File: TS39) Conclusion No cytotoxicity can be detected at concentrations up to 100%.
Endotoxicity and Cytotoxicity Studies 1) Aug 2005 In Vitro Chromosomal Aberration Study Cytotoxicity (File: TS39) Chinese Hamster Ovary (CHO) cells were grown in monolayer with and without metabolic activation.
More informationCLINICAL POLICY Department: Medical Management Document Name: Opdivo Reference Number: CP.PHAR.121 Effective Date: 07/15
Page: 1 of 6 IMPORTANT REMINDER This Clinical Policy has been developed by appropriately experienced and licensed health care professionals based on a thorough review and consideration of generally accepted
More informationNew epigenetic agents: therapeutic approach in cancer
New epigenetic agents: therapeutic approach in cancer Madrid, 2 de julio de 2014 Outline Institution: CIMA Project Partnering Opportunities 2 WHAT IS CIMA? CIMA The Center for Applied Medical Research
More informationGive a NOD to diabetes:
Give a NOD to diabetes: NOD proteins ti link immunity it and metabolism tbli Jonathan Schertzer McMaster University McMaster University Faculty of Health Sciences Department of Biochemistry and Biomedical
More informationThe Ultimate Healthcare & Biotechnology Event in 2010. Deborah Rathjen CEO & Managing Director 24 March 2010
The Ultimate Healthcare & Biotechnology Event in 2010 Deborah Rathjen CEO & Managing Director 24 March 2010 Safe Harbor Statement Factors Affecting Future Performance This presentation contains "forward-looking"
More informationData Visualization in Cheminformatics. Simon Xi Computational Sciences CoE Pfizer Cambridge
Data Visualization in Cheminformatics Simon Xi Computational Sciences CoE Pfizer Cambridge My Background Professional Experience Senior Principal Scientist, Computational Sciences CoE, Pfizer Cambridge
More informationGuidance. 2. Definitions. 1. Introduction
Work with naked DNA or RNA (including oligonucleotides, sirna, mirna, sequences that code for highly biologically active molecules and full length viral genomes) Guidance 1. Introduction The following
More informationIMMUNOMEDICS, INC. February 2016. Advanced Antibody-Based Therapeutics. Oncology Autoimmune Diseases
IMMUNOMEDICS, INC. Advanced Antibody-Based Therapeutics Oncology Autoimmune Diseases February 2016 Forward-Looking Statements This presentation, in addition to historical information, contains certain
More informationCCR Biology - Chapter 9 Practice Test - Summer 2012
Name: Class: Date: CCR Biology - Chapter 9 Practice Test - Summer 2012 Multiple Choice Identify the choice that best completes the statement or answers the question. 1. Genetic engineering is possible
More informationDelivering gene therapy to patients
Delivering gene therapy to patients FORWARD-LOOKING STATEMENTS This presentation contains forward-looking statements that involve substantial risks and uncertainties. All statements, other than statements
More informationDaiichi Sankyo to Acquire Ambit Biosciences
For Immediate Release Company name: DAIICHI SANKYO COMPANY, LIMITED Representative: Joji Nakayama, Representative Director, President and CEO (Code no.: 4568, First Section, Tokyo Stock Exchange) Please
More informationmicrornas Non protein coding, endogenous RNAs of 21-22nt length Evolutionarily conserved
microrna 2 micrornas Non protein coding, endogenous RNAs of 21-22nt length Evolutionarily conserved Regulate gene expression by binding complementary regions at 3 regions of target mrnas Act as negative
More informationNew Advances in Cancer Treatments. March 2015
New Advances in Cancer Treatments March 2015 Safe Harbour Statement This presentation document contains certain forward-looking statements and information (collectively, forward-looking statements ) within
More informationNot All Clinical Trials Are Created Equal Understanding the Different Phases
Not All Clinical Trials Are Created Equal Understanding the Different Phases This chapter will help you understand the differences between the various clinical trial phases and how these differences impact
More information